AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JUN 18 - (NewsRx.com & NewsRx.net) -- The immune response to pneumococcal revaccination in older adults has been investigated.
According to a study from the United States, "As individuals advance in age, the risk of infection, bacteremia, and mortality caused by Streptococcus pneumoniae rises. Retrospective data demonstrate that the licensed penumococcal polysaccharide vaccine (PPV) is effective in older persons in reducing serotype-specific invasive disease. PPV demonstrates good immunogenicity in older adults, generally comparable to that in younger subjects, although certain cohorts respond less well."
"The response to PPV is T cell independent, however, and does not elicit immunologic memory," said Andrew S. Artz and associates at the Institute for Advanced Studies in Aging and Geriatric Medicine in Washington, DC, and the National Institute on Aging in Baltimore, Maryland. "The duration of the anti-capsular polysaccharide antibody response appears to wane as early as three years after vaccination. In older persons, revaccination induces an antibody response, although it may not be as strong as that from the initial vaccine."
"While revaccination of older adults has been recommended, clinical efficacy has not yet been proven," reported Artz and his coauthors. "Measures of ...